Herbert Irving Comprehensive Cancer Center

What to Know About Liquid Biopsies for Cancer Liquid biopsies have the potential to transform cancer care. We asked Dr. Chin Hur how these tests fit into the future of personalized cancer screening, now that one has FDA approval.

The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...

The Spring/Summer issue of Accelerations is here!
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...

Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy.
engineering.columbia.edu/about/news/t...

Uterine Cancer Rates Predicted to Rise, Especially Among Black Women A new study forecasts a substantial rise in uterine cancer cases and deaths over the next three decades, with a disproportionate impact on Black women.

Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...

Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...

2025 IICD Intensive Workshop first day in classroom

Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social

Tattoos and Skin Cancer: A Cause for Concern? Mariam El-Ashmawy, MD, PhD, shares what you need to know about tattoos and skin cancer—and how to protect your skin for the long run.

Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...

Brent Stockwell presenting to SRP

The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social

Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social

Highlights from HICCC's 3rd Annual Clinical Trials Day at
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials

6/3, 10:45 AM EST/9:45 AM CDT , A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Authors: Vadim Spektor. meetings.asco.org/2025-asco-an...

6/3, 10:45 AM EST/ 9:45 AM, Does the Road to Cure Myeloma End with Minimal Residual Disease?. Discussant: Suzanne Lentzsch, MD, PhD. meetings.asco.org/2025-asco-an...

View today's final HICCC #ASCO2025 daily roundup, below!

6/2, 8:00 AM CDT, Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
Author: Aya Haggiagi
meetings.asco.org/2025-asco-an...

6/2, 9:45 AM CDT, A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
Author: Alexander Wei. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...

View today's HICCC #ASCO2025 daily roundup, below!

5/31, 1:15 PM CDT. Phase I/Ib study of INAVO alone and in combination with endocrine therapy ± palbociclib in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer.
Author: Melissa Accordino
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
Author: Ran Reshef
meetings.asco.org/2025-asco-an...

5/31, 3:00 PM CDT. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
Presenter: Fabio Massaiti Iwamoto
meetings.asco.org/2025-asco-an...

5/31, 8:00 AM CDT, Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
Presenter: Sara Wallam
meetings.asco.org/2025-asco-an...

View today's HICCC #ASCO25 daily research roundup, below!

5/30, 2:45 PM , A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.
Author: Andrew Lassman.
meetings.asco.org/2025-asco-an...

5/30, 2:45 PM , A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Author: Ran Reshef.
meetings.asco.org/2025-asco-an...

View today's HICCC #ASCO2025 daily roundup, below!

Headed to #ASCO2025 ?! 🔬✈️
Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social !
Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...

Answering 10 Commonly Asked Questions About Cancer Clinical Trials We answer 10 of the most common—and often misunderstood—questions about how cancer clinical trials work, who they’re for, and why they matter.

Nearly everything we know about cancer started in a clinical trial. But what are clinical trials really like?
💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...

Cancer research is a team effort. 🌎🔬This #CancerResearchMonth the HICCC thanks everyone who makes life-changing breakthroughs possible at Columbia. @columbiamed.bsky.social

Disrupting the Blood-Brain Barrier to Improve Glioblastoma Treatment | Spotlight | Advances in Neurology and Oncology | NewYork-Presbyterian NewYork-Presbyterian neurosurgeon Dr. Brian Gill describes the SONOBIRD trial, which tests a new implantable ultrasound device that may improve drug delivery to the brain to treat glioblastoma.

Neurosurgeons at NYP / @columbiamed.bsky.social / @weillcornell.bsky.social are studying a new ultrasound tech to help drugs reach glioblastoma tumors. The SONOBIRD trial tests a device that disrupts the blood-brain barrier. More from Dr. Brian Gill below. 🧠 💊 nyp.org/advances/art...